Contents:

EXECUTIVE SUMMARY Scope Datamonitor insight into the diabetes market Key metrics DIABETES MARKET DEFINITION Market definition Therapy classes covered Disease indications Epidemiology overview Methodology for determining 2001 prevalence of diabetes Forecast prevalence of diabetes to 2025 Diabetes drug class definitions Insulin Sulphonylureas Biguanides Glitazones Alpha glucosidase inhibitors Prandial glucose regulators Definition of gold standards Class comparisons GLOBAL MARKET ANALYSIS Overview of global diabetes market Key trends in the global diabetes market Insulins Overview of the global insulin market Key trends in the global insulin market Comparison of key brands in the insulin class Novolin Humulin Humalog Insuman Lantus NovoLog Sulphonylureas Overview of the global sulphonylurea market Key trends in the global sulphonylurea market Comparison of key brands in the sulphonylurea class Amaryl Glucotrol and Glucotrol XL Biguanides Overview of the global biguanide market Key trends in the global biguanide market Comparison of key brands in biguanide class Glucophage, Glucophage XR and Glucovance Glitazones Overview of the global glitazone market Comparison of key brands in the glitazone class Avandia Actos Alpha glucosidase inhibitors Overview of the global AGI market Key trends in the global AGI market Comparison of key brands in the AGI class Basen Precose Prandial glucose regulators Overview of the global PGR market Comparison of key brands in the PGR class Prandin Starlix COUNTRY ANALYSIS Significance of major countries in the global diabetes market Overview of the global diabetes market Breakdown of the country markets by class Summary of global market factors The US Japan Europe The US diabetes market Environmental drivers in the US Positive impacts: The Japanese diabetes market Environmental drivers in Japan The French diabetes market Environmental drivers in France The German diabetes market Environmental drivers in Germany The Italian diabetes market Environmental drivers in Italy The Spanish diabetes market Environmental drivers in Spain The UK diabetes market Environmental drivers in the UK LIFECYCLE MANAGEMENT Global drug class lifecycle in the diabetes market Reformulations in the diabetes market Lifecycle management case studies Novo Nordisk—additional formulation aid battle against Lilly Inhalation insulins—are they really the answer to the formulation problem? BMS—protecting its Glucophage franchise Pfizer and Warner-Lambert—the good, the bad, and Rezulin Supergenerics—waiting to take over the market when patents expire THE FUTURE DECODED Market forecasting methodology Diabetes market growth Diabetes drug class growth Individual drug growth Trends in the diabetes market to 2008 Diabetes market forecast Positive and negative drivers in the diabetes market, 2001–2008 Diabetes market forecast by drug class Insulin class forecast Positive and negative drivers in the insulin class, 2001–2008 Insulin sales forecast to 2008 Sulphonylurea class forecast Positive and negative drivers in the sulphonylurea class Sulphonylurea sales forecasts to 2008 Biguanide class market forecast Positive and negative drivers in the biguanide class market, 2001–2008 Biguanide sales forecasts to 2008 Glitazone class forecast Positive and negative drivers in the glitazone class Glitazone sales forecast to 2008 AGI class forecast Positive and negative drivers in the AGI class AGI product sales forecast to 2008 PGR class forecast Positive and negative drivers in the PGR class, 2001–2008 PGR product sales forecast to 2008 Product forecast summary Alternative forecast scenario APPENDIX Datamonitor’s Immune Disorders and Inflammation (IDI) Business Unit Contributing experts Table of tables Table of figures Bibliography Epidemiology sources for prevalence data Sales data research methodology Introduction Hypothesis formulation Hypothesis testing Data verification with key contacts Quality control Quantification of data reliability Confidence ratings Exchange rates Patent data